Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (October 2019)

39 slides from Windtree Therapeutics's investor presentation, Oct 25, 2019

  1. Slide 1: Windtree Therapeutics, Inc. Corporate Presentation

    Windtree Therapeutics, Inc. Corporate Presentation October 2019 WINDTREE THERAPEUTICS OTCQB: WINT

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements To the extent that statements in this presentation are not strictly historical, including statements about the Company's clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agree

  3. Slide 3: Windtree Investment Highlights

    Windtree Investment Highlights = Late-stage pipeline of novel cardiovascular and pulmonary programs * Three phase 2 clinical programs and additional pre-clinical pipeline candidates in both cardiovascular and pulmonary indications = Lead cardiovascular program, istaroxime (ista), is a first-in-class

  4. Slide 4: Windtree Therapeutics Portfolio

    Windtree Therapeutics Portfolio Late Stage Programs in Cardiovascular and Acute Pulmonary Cardiovascular Istaroxime for the Treatment of Acute Heart Failure + Pre-Clinical Oral, Heart Foilure Candidates and Programs: cv-ist2 SERCA2a (Next Generation Dual (Selective Action) Action SERCA2a) Oral & iv.

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones + Three late-stage programs focused on significant markets with unmet needs + Multiple clinical and business milestones which have the potential to be catalysts Highly-experienced management team conducting smart, rigorous execution and leveraging oppor

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure @ and Early Cardiogenic Shock S@ winotree a6

  7. Slide 7: Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need

    Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = 6 million patients in the U.S. and over 18 million worldwide. The prevalence of HF is on the rise as is mortality = #1 cause of hospitalizations in patients over 65 years old in the United States and Western Europe w

  8. Slide 8: Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need

    Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = Despite the need, there have not been meaningful new therapeutic advancements in acute heart failure for decades = Current approaches to improve acute cardiac dysfunction are associated with unwanted effects: *

  9. Slide 9: Cardiac Output, Blood Pressure and Renal Function are Critical

    Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF Patients and Their Outcomes Early drop in systolic blood pressure ‘and worsening renal function in acute heart In-Hospital Mortality Rates by Admission upper vegier Meenas am Systolic Blood Pressure Deciles (n = 4

  10. Slide 10: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy ™ Novel intravenous agent designed to improve systolic contraction and diastolic relaxation and fill function of the heart = Unique, dual mechanism of effect that has been shown to impact both systolic and diastolic dysfunction © Inhibition of the sodium-pot

  11. Slide 11: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study = Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% * SBP 90-150 mmHg = N=120 (30/group) * Significant improvement in PC

  12. Slide 12: Istaroxime Phase 2b Study Design and Measures

    Istaroxime Phase 2b Study Design and Measures = After a positive phase 2a trial, the predecessor company conducted a phase 2b trial that was multicenter, double blind, placebo-controlled, parallel group = Hospitalized for recurrent AHF (dyspnea plus need for IV furosemide 240 mg); adult population *

  13. Slide 13: Primary Endpoint — Significant Changes in E/e' Ratio

    Primary Endpoint — Significant Changes in E/e' Ratio istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo 20 20 10 00 10 5.20 “30 50 60 _ Infusion period no Infusion period Baseline 6hours 24hours 48 hours Baseline 6hours 24hours 48 hours @ Placebo - Cohort 1 —@-Istaroxime 0.5 y

  14. Slide 14: Substantial Change in Stroke Volume Index

    Substantial Change in Stroke Volume Index 80 70 60 50 40 30 20 10 VI (mi/beat/m?) 0.0 “10 20 istaroxime 0.5 yg/kg/min vs. placebo ‘SV (mlbeat/in?) 80 70 60 50 40 30 20 10 00 istaroxime 1.0 pg/kg/min vs. placebo ] Infusion period “1.0 20 ——— Infusion period Baseline hours 24hours 48 hours =@~ Placebo

  15. Slide 15: Systolic Blood Pressure Maintained or Increased During Treatment

    Systolic Blood Pressure Maintained or Increased During Treatment istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo mo Be = = —* £* 3 an B B s £0 & | Ss Es Es 2 2 G4 os 2 ~@> Placebo - Cohort 1 -@= Istaroxime 0.5 yg/Kg/min Placebo - Cohort 2 ~@=Istaroxime 1.0 ug/Kg/min * prval

  16. Slide 16: eGFR Maintained or Improved with Istaroxime

    eGFR Maintained or Improved with Istaroxime istaroxime 0.5 wg/kg/min vs. placebo istaroxime 1.0 ug/kg/min vs. placebo 2 20 5 Infusion period ts fusion period 10 10 & i Placebo - Cohort 2 GER (mL/min/m?) eGFR (mL/min/m?) =~ Placebo Cohort» e taroxime 05 us/Kevmin Oe storoxime 10 ue/Ke/min Baseline 24

  17. Slide 17: Heart Rate was Lowered During Treatment

    Heart Rate was Lowered During Treatment Change in Heart Rate (bpm) istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo owann Change in Heart Rate (bpm) == Placebo -Cohort 1 ~@- [staroxime 05 yg/Ke/iin * pvalue= 0.014 ry Tnfusion period @ ££ SF Re eo eos s of ee eH 1saroxne 0 pa

  18. Slide 18: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically significant arrhythmias Clinically significant arrhythmias 220% 105% 105% 105% 100% 3% 0K 200% 20% _ 60% _ 0% I 40% = eS a sae 20% som 00% 00% Beene ay i(tuser) Day? exzine it Day? lacebo-Cehor 1 misaroimed.s yalkg/min sePlacebo-Co

  19. Slide 19: No Meaningful Increases in Troponin (cTnT) During Treatment

    No Meaningful Increases in Troponin (cTnT) During Treatment cInt -0 to24 hours Int -24to 72 hours x0 so 5 6 “ “ s SSS! s== x x» 2s s x» x» 03 6 8 2 as aa me u % & © 7 ActnT—0to24hours AcTnT -24to 72 hours . ‘ os aes 3 2 a i 2 2 o 3 6 9 2 w w nm 2 xs «@ o @ 05 uela/min —e— 1.0 uala/min = 9 = Placebo

  20. Slide 20: Adverse Events

    Adverse Events Istaroxime 0.5 istaroxime 1.0 con ca main popaae (n=41) ) All adverse events, 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to pablo 1 (2.6%) : 4 (10.0%) Serious adverse events 2 (5.1%) 2 (4.9%) 6 (15.0%) Cardiac death : - 1 (2.5%) Cardiogenic shock = z 1(25%)* Cardiac fail

  21. Slide 21: Istaroxime Phase 2b Study - Summary

    Istaroxime Phase 2b Study - Summary * A 24-hour infusion of istaroxime at doses of 0.5 and 1.0 mg/kg/min was associated with significant improvements in diastolic and systolic cardiac function at 24 hours. * The primary endpoint, E/e’ at 24 hours, was significantly (p<0.05) improved by both doses of

  22. Slide 22: Istaroxime — Acute Heart Failure — Program Status

    Istaroxime — Acute Heart Failure — Program Status 1. The Company has worked with top Heart Failure advisors and has had positive engagement and guidance from the FDA v_ The FDA granted Fast Track designation to the program in July 2019 2. The Company plans to transition istaroxime to phase 3-ready a

  23. Slide 23: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway " Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output * Approximately 110,000 pat

  24. Slide 24: Istaroxime — Early Cardiogenic Shock

    Istaroxime — Early Cardiogenic Shock = FDA continues to recognize cardiogenic shock as an unmet medical need = FDA has outlined their current regulatory position regarding approval of drugs for shock © Sponsors are not required to show a benefit other than an increase in blood pressure to support ap

  25. Slide 25: Istaroxime SBP Change from Baseline, Phase 2a and 2b Dose Groups

    Istaroxime SBP Change from Baseline to 6 or 24 Hours from the Phase 2a and 2b Dose Groups Istaroxime has the potential to improve blood pressure and organ perfusion in patients with AHF 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change + S

  26. Slide 26: Rationale for Istaroxime in Early Cardiogenic Shock

    Rationale for Istaroxime in Early Cardiogenic Shock = Dose related changes in systolic blood pressure in the phase 2 clinical program suggest a meaningful increase in blood pressure may be achieved in early cardiogenic shock by istaroxime = Improving systolic and diastolic cardiac function without i

  27. Slide 27: Novel Heart Failure Portfolio

    Novel Heart Failure Portfolio- é Oral and IV SERCA2a Activators for Chronic & Acute Heart Failure {% y Dual Mechanism SERCA2a Selective SERCA2a Activators Activators = SERCA2a activators with Na*/K* = Selective SERCA2a Activators devoid of pump inhibitory activities any Na*/K* pump inhibitory activi

  28. Slide 28: AEROSURF

    AEROSURF*® Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS

  29. Slide 29: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf

  30. Slide 30: Clinicians Seeking a Noninvasive Way to Deliver Surfactant

    Clinicians Seeking a Noninvasive Way to Deliver Surfactant What is wanted?: v Avoid the risks, complications and clinical instability associated with delivery of surfactant therapy via intubation and mechanical ventilation Y Possibility of repeat doses v Enable administration by non- specialist staf

  31. Slide 31: Windtree Technology Platform

    Windtree Technology Platform - Proprietary Synthetic KL4 Surfactant AEROSURF® Structurally similar to human lung surfactant Liquid KLs surfactant (intratracheal instillate) for RDS approved by the FDA lyophilized KLs surfactant currently being developed for AEROSURF 33 Utilizing pressure and heated

  32. Slide 32: AEROSURF - Potential to Impact on the Clinical Course of RDS

    AEROSURF® - Potential to Impact on the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment ® Improved Long-Term AEROSURF Respiratory Outcomes Study results across each Faramieters of these important + parameters show evidence 1 of the potential to impa

  33. Slide 33: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach Program Evolution = The four phase 2a and 2b clinical trials have reproduced efficacy in reducing nCPAP failure and the need for intubation and observed important positive BPD data. © AEROSURF has received Fast

  34. Slide 34: Rostafuroxin

    Rostafuroxin for genetically targeted resistant hypertension and renal impairment SQ winotree

  35. Slide 35: Hypertension Market — A Unique, Genetically-Targeted Approach

    Hypertension Market — A Unique, Genetically-Targeted Approach * Hypertension is a very large market with high unmet need * Over 1/3 of the adult population in the U.S. has hypertension and the majority of treated patients (50-85% globally) do not reach target for control. Well known that ethnicity c

  36. Slide 36: Rostafuroxin Next Steps

    Rostafuroxin Next Steps 1. Complete pharmaceutical development work for final formulation 2. Continue ongoing work to explain the ethnic differences seen in the Phase 2b clinical trial, including a more sensitive assay to measure drug concentration 3. Seek to develop rostafuroxin into an asset that

  37. Slide 37: Financial Update

    Financial Update As of June 30, 2019 = Cash and marketable securities of $6.1 million as of June 30, 2019 * Supports development activities, operations and debt service through October 2019 * The Company is actively engaged in discussions with a number of potential counterparties to secure additiona

  38. Slide 38: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones Ista: conduct clinical study of early cardiogenic shock to explore potential accelerated pathway for approval of this indication. Complete ista phase 2 clinical program and develop strong phase 3 and partnership position; to create added value, advance

  39. Slide 39: Windtree Therapeutics

    Windtree Therapeutics “Striving to deliver Hope for a Lifetime!” SQ winotree a6

Windtree Therapeutics — Investor Presentation (October 2019) on 6ix